Generate Biomedicines(GENB)
Search documents
Generate Biomedicines Begins IPO Push With Major Collaboration Deals
Seeking Alpha· 2026-02-06 18:16
Core Insights - Donovan Jones is an IPO research specialist with 15 years of experience analyzing investment opportunities for U.S. IPOs [1] - He leads the investing group IPO Edge, which provides actionable information on growth stocks through various resources [1] Group 1: IPO Edge Services - IPO Edge offers first-look IPO filings, previews on upcoming IPOs, and an IPO calendar for tracking future listings [1] - The platform includes a database of U.S. IPOs and a guide to IPO investing, covering the entire IPO lifecycle from filing to listing [1]
Generate Biomedicines(GENB) - Prospectus
2026-02-04 22:02
As filed with the Securities and Exchange Commission on February 4, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Generate Biomedicines, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 83-1630228 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 101 South Street, Suite 900 Somerville, MA 02143 (8 ...